Dysregulated PI3K/AKT signaling in oral squamous cell carcinoma: The tumor microenvironment and epigenetic modifiers as key drivers
Open Access
- 1 January 2025
- journal article
- Published by Tech Science Press in Oncology Research
- Vol. 33 (8) , 1835-1860
Abstract
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway is one of the most frequently dysregulated signaling networks in oral squamous cell carcinoma (OSCC). Although the tumor microenvironment (TME) and epige... | Find, read and cite all the research you need on Tech Science PressKeywords
This publication has 152 references indexed in Scilit:
- A Meta-analysis of the Risk of Adverse Cardiovascular Events in Patients with Cancer Treated with Inhibitors of the PI3K/AKT/mTOR Signaling PathwayCardiovascular Toxicology, 2024
- Novel non‐invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non‐coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathwayCancer Medicine, 2024
- Network pharmacological analysis and experimental study of cucurbitacin B in oral squamous cell carcinomaMolecular Diversity, 2023
- Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinomaCancer Medicine, 2023
- Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaInvestigational New Drugs, 2021
- Role of PI3K/AKT pathway in cancer: the framework of malignant behaviorMolecular Biology Reports, 2020
- Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF‐κΒ/STAT3 signalling axis in oral squamous cell carcinoma modelsIUBMB Life, 2019
- Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cellsCancer Chemotherapy and Pharmacology, 2018
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesTargeted Oncology, 2017
- Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In VitroJournal of Cellular Biochemistry, 2016